All In Biotech

Drug Trial Radar · NCT07297329

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

292

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Conditions

  • Multiple Myeloma (MM)

Interventions

  • SCTC21CDrug

    Pharmaceutical form: Solution for infusion; Route of administration: Subcutaneous

  • BortezomibDrug

    Pharmaceutical form: Lyophilized powder for injection; Route of administration: Subcutaneous

  • LenalidomideDrug

    Pharmaceutical form: Capsules; Route of administration: Oral

  • DexamethasoneDrug

    Pharmaceutical form: Tablets, ampoules or vials for injection; Route of administration: Oral/Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: Up to approximately 84 months after the First Participant In (FPI)
  2. Minimal residual disease (MRD) negativity rate for participants with CRTime frame: Up to approximately 84 months after the FPI

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.